Clinical trial

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

NCT03608007

Study summary

ClinicalTrials.gov

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention X-396 Capsule Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-06-15

PhasePHASE2

Conditions

Lung Cancerverified · MONDO: lung cancer

ROS1 Gene Rearrangementunresolved

Interventions

X-396 CapsuleDRUG

Sponsors & collaborators

Betta Pharmaceuticals Co., Ltd.lead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03608007 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.